Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Systemic sclerosis
•
Interstitial lung disease
•
Scleroderma
•
Pulmonary
Would nintedanib offer benefit to a patient with scleroderma (Anti-Th/To+/SSA+) who has CT chest with typical UIP pattern?
Related Questions
How would you approach management of a patient with rapidly progressive systemic sclerosis with worsening skin disease, myositis, arthritis, dysphagia and failure to thrive developing within 6 months?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
How would you manage a patient with diffuse Systemic Sclerosis who develops severe rapidly progressive calcinosis?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
Do you avoid the use of TNF inhibitors in patients with RA-ILD?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
How do you manage patients with systemic sclerosis and chronic thrombotic microangiopathy on renal biopsy, but no other evidence of scleroderma renal crisis?
Would you consider rituximab in a patient with severe GI dysmotility caused by scleroderma?
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
What is your approach to using nintedanib in patients on baseline immunosuppression?
